|
SFRS5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.84194889843548E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.56379966940324E-10 |
| Normal-vs-Stage2 |
7.76969999449761E-09 |
| Normal-vs-Stage3 |
1.41070044534786E-10 |
| Normal-vs-Stage4 |
2.60729999812526E-08 |
| Stage1-vs-Stage2 |
1.149640E-01 |
| Stage1-vs-Stage3 |
1.335830E-01 |
| Stage1-vs-Stage4 |
1.440430E-01 |
| Stage2-vs-Stage3 |
6.565000E-01 |
| Stage2-vs-Stage4 |
9.148600E-01 |
| Stage3-vs-Stage4 |
7.518200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.85550463882578E-11 |
| Normal-vs-AfricanAmerican |
1.035230E-03 |
| Normal-vs-Asian |
6.12549999999823E-05 |
| Caucasian-vs-AfricanAmerican |
4.950000E-01 |
| Caucasian-vs-Asian |
2.093800E-01 |
| AfricanAmerican-vs-Asian |
8.291400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.23090443288265E-11 |
| Normal-vs-Female |
3.03510550025976E-11 |
| Male-vs-Female |
5.836200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.46059950193001E-10 |
| Normal-vs-Age(41-60Yrs) |
5.80670000971395E-09 |
| Normal-vs-Age(61-80Yrs) |
7.08390013315352E-11 |
| Normal-vs-Age(81-100Yrs) |
4.45260000000447E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.147600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.752400E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.726800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.113610E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.819400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.892600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.640700E-04 |
| Classical-VS-Follicular |
1.694190E-01 |
| Classical-VS-Other |
4.329400E-01 |
| Classical-VS-Normal |
3.0415003848816E-10 |
| Tall-VS-Follicular |
5.712300E-02 |
| Tall-VS-Other |
3.612800E-01 |
| Tall-VS-Normal |
4.31259472577494E-11 |
| Follicular-VS-Other |
8.545400E-01 |
| Follicular-VS-Normal |
7.60710000546894E-08 |
| Other-VS-Normal |
5.238700E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.8430591214601E-12 |
| Normal-vs-N1 |
1.812750E-04 |
| N0-vs-N1 |
3.008400E-01 |
|
|
